Related references
Note: Only part of the references are listed.Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
C. R. A. Silveira et al.
BMC NEUROLOGY (2019)
Parkinson's disease in the Western Pacific Region
Shen-Yang Lim et al.
LANCET NEUROLOGY (2019)
Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
Stephen Mullin et al.
MOVEMENT DISORDERS (2019)
Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials
Frederick L. Hitti et al.
PARKINSONISM & RELATED DISORDERS (2019)
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
Mike A. Nalls et al.
LANCET NEUROLOGY (2019)
LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients
Daniel Ysselstein et al.
NATURE COMMUNICATIONS (2019)
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
S. Pablo Sardi et al.
MOVEMENT DISORDERS (2018)
Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease
Cornelis Blauwendraat et al.
JAMA NEUROLOGY (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
Lysosomal storage diseases
Frances M. Platt et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort
Kenneth Marek et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
S. Pablo Sardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
Anna Migdalska-Richards et al.
SYNAPSE (2017)
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
Hien Tran Zhao et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Frequency of GBA Variants in Autopsy-proven Multiple System Atrophy
Miriam Sklerov et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2017)
mTOR Signaling in Growth, Metabolism, and Disease (vol 168, pg 960, 2017)
Robert A. Saxton et al.
CELL (2017)
Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
Benjamin McMahon et al.
NEURAL REGENERATION RESEARCH (2016)
Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies
Joshua T. Geiger et al.
NEUROBIOLOGY OF DISEASE (2016)
Advances in GSA-associated Parkinson's disease - Pathology, presentation and therapies
Melinda Barkhuizen et al.
NEUROCHEMISTRY INTERNATIONAL (2016)
A New Initiative on Precision Medicine
Francis S. Collins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N. Fuji et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Rising to the Challenges of Clinical Trial Improvement in Parkinson's Disease
Soania Mathur et al.
JOURNAL OF PARKINSONS DISEASE (2015)
Computational analysis of the LRRK2 interactome
Claudia Manzoni et al.
PEERJ (2015)
Novel recruitment strategy to enrich for LRRK2 mutation carriers
Tatiana Foroud et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2015)
Ten Years and Counting: Moving Leucine-Rich Repeat Kinase 2 Inhibitors to the Clinic
Andrew B. West
MOVEMENT DISORDERS (2015)
Variants associated with Gaucher disease in multiple system atrophy
Jun Mitsui et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
Alisdair McNeill et al.
BRAIN (2014)
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
Mike A. Nalls et al.
NATURE GENETICS (2014)
Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling
Huma Q. Rana et al.
GENETICS IN MEDICINE (2013)
RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson's Disease Risk
David A. MacLeod et al.
NEURON (2013)
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
S. Pablo Sardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
LRRK2: Cause, Risk, and Mechanism
Coro Paisan-Ruiz et al.
JOURNAL OF PARKINSONS DISEASE (2013)
mTOR Inhibition Alleviates L-DOPA-Induced Dyskinesia in Parkinsonian Rats
Mickael Decressac et al.
JOURNAL OF PARKINSONS DISEASE (2013)
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Matthew E. Gegg et al.
ANNALS OF NEUROLOGY (2012)
Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
Joseph R. Mazzulli et al.
CELL (2011)
Glucocerebrosidase mutations in diffuse Lewy body disease
Kenya Nishioka et al.
PARKINSONISM & RELATED DISORDERS (2011)
Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-beta Levels in a Mouse Model of Alzheimer's Disease
Patricia Spilman et al.
PLOS ONE (2010)
Association of Glucocerebrosidase Mutations With Dementia With Lewy Bodies
Lorraine N. Clark et al.
ARCHIVES OF NEUROLOGY (2009)
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Gustavo H. B. Maegawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
GLUCOCEREBROSIDASE MUTATIONS IN 108 NEUROPATHOLOGICALLY CONFIRMED CASES OF MULTIPLE SYSTEM ATROPHY
B. Segarane et al.
NEUROLOGY (2009)
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
E. Sidransky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gaucher disease:: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Kathleen S. Hruska et al.
HUMAN MUTATION (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset
Z. Gan-Or et al.
NEUROLOGY (2008)
Carrier screening for Gaucher disease - Lessons for low-penetrance, treatable diseases
Shachar Zuckerman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease
L. N. Clark et al.
NEUROLOGY (2007)
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
Mahaboobi Jaleel et al.
BIOCHEMICAL JOURNAL (2007)
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders
O. Goker-Alpan et al.
NEUROLOGY (2006)
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population
M Toft et al.
NEUROLOGY (2006)
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews
LJ Ozelius et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
